[Inhibitors of HMG-CoA reductase in prevention of osteoporosis and bone fractures. Similar mechanism of action of statins and bisphosphonates].
Stajszczyk
Marcin
M
Klinika Chorób Wewnetrznych i Chemioterapii Onkologicznej Sl. AM Katowice. marcins(at)mp.pl
Mykała-Cieśla
Joanna
J
D000368:Aged; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy; D001842:Bone and Bones / Q000187:drug effects; D002478:Cells, Cultured; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*
D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
Inhibitory reduktazy HMG-CoA w prewencji osteoporozy i złamań kości. Podobny mechanizm działania statyn i bifosfonianów.